02.01.13	Pharmos Corp. Designates Eric Fangmann as Acting President and Acting Chief Financial Officer
17.10.12	Pharmos Corp. Announces Management Changes
30.07.12	Pharmos Corp. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2012
17.05.12	Pharmos Corp. Announces Successfully Completion of Proof-Of-Concept Clinical Trial Using its Compound Levotofisopam to Treat Patients with Hyperuricemia and Gout
16.04.12	Pharmos Corp. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2012